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Calcium(Ca
2+)signalingplaysakeyroleinawiderangeofphysiologicalfunctionsincludingcontrolofcardiacandskeletalmuscle
performance. To assure a precise coordination of both temporally and spatially transduction of intracellular Ca
2+ oscillations to
downstreamsignalingnetworksandtargetoperations,Ca
2+ cyclingregulationinmuscletissueisconductedbyaplethoraofdiverse
molecules. Ca
2+ S100A1 is a member of the Ca
2+-binding S100 protein family and represents the most abundant S100 isoform in
cardiac and skeletal muscle. Early studies revealed distinct expression patterns of S100A1 in healthy and diseased cardiac tissue
from animal models and humans. Further elaborate investigations uncovered S100A1 protein as a basic requirement for striated
muscle Ca
2+ handling integrity. S100A1 is a critical regulator of cardiomyocyte Ca
2+ cycling and contractile performance. S100A1-
mediated inotropy unfolds independent and on top of βAR-stimulated contractility with unchanged βAR downstream signaling.
S100A1hasfurtherbeendetectedatdiﬀerentsiteswithinthecardiac sarcomereindicatingpotentialrolesinmyoﬁlament function.
More recently, a study reported a mitochondrial location of S100A1 in cardiomyocytes. Additionally, normalizing the level of
S100A1 protein by means of viral cardiac gene transfer in animal heart failure models resulted in a disrupted progression towards
cardiacfailureandenhancedsurvival.ThisbriefreviewisconﬁnedtothephysiologicalandpathophysiologicalrelevanceofS100A1
in cardiac and skeletal muscle Ca
2+ handling with a particular focus on its potential as a molecular target for future therapeutic
interventions.
1.Introduction
Ca2+ is a highly versatile intracellular signal that controls
many diﬀerent cellular functions. Therefore, Ca2+ signals
need to be ﬂexible yet precisely regulated. Besides con-
trolling gene transcription and growth, Ca2+ regulates the
contraction and relaxation in muscles tissue. Skeletal and
cardiac muscle belong to the striated tissue and share many
functional aspects. The Ca2+ signals require downstream
proteins to connect Ca2+ oscillations to diﬀerent signaling
domains. Ca2+ cycling in muscle tissue is regulated by a
plethora of proteins, transmitting the Ca2+ messages with
precision and in a temporally and spatially coordinated
manner. One of these speciﬁc Ca2+ binding protein families
within muscle cells is the S100 protein family.
The process of excitation-contraction coupling (ECC)
in skeletal and cardiac muscle cells requires membrane
depolarization. After membrane depolarization, Ca2+ inﬂux
is activated via voltage-gated L-type Ca2+ channels into the
cytosol of both skeletal muscle cells and cardiac myocytes
[1].ThisriseincytoplasmicCa2+ concentrationleadstoCa2+
release from the sarcoplasmic reticulum (SR) (Ca2+ induced
Ca2+ release-CICR) by activation of Ryanodine receptors
(RyR), whereas in skeletal muscle voltage dependent Ca2+
release occurs (VICR). After Ca2+ release of the RyR, Ca2+
molecules subsequently bind to the contractile proteins such
as troponin c, which causes contraction of the myocytes.
Thereafter, Ca2+ is cleared from the cytosol by reuptake of
Ca2+ into the SR by the action of a sarcoplasmic reticulum
Ca2+ ATPase (SERCA).2 Journal of Biomedicine and Biotechnology
Much evidence has accumulated that abnormal regula-
tion of intracellular Ca2+ by the SR plays a key role in the
development of cardiac diseases. A decreased Ca2+ transient
leads to a decreased contractility of the cardiomyocytes. The
reduced Ca2+ transients are mainly related to a decreased SR
Ca2+ load. Correction of the disorder of Ca2+ cycling has a
potential as a new and intriguing therapeutic strategy against
cardiac disease states.
Among others proteins, it has been proven that S100A1
regulates sarcoplasmic reticulum Ca2+ handling in skeletal
and cardiac muscles [2, 3]. In this brief review, we discuss
the physiological role of S100A1 in the regulation of ECC
in skeletal and cardiac muscles. In addition, we focus on
pathophysiological consequences of altered S100A1 expres-
sion in cardiovascular disease to provide a comprehensive
understanding of the role of S100A1. Finally, we aim to
highlight the potential of an S100A1-targeted therapy in
cardiovascular diseases.
2. S100 ProteinFamily
S100 Ca2+-binding proteins are the largest subfamily of
EF-hand proteins (25 human genes), putatively targeting
more than 90 proteins (previously reviewed in [4, 5]).
S100 proteins are small acidic proteins (10–12kDa) that are
found exclusively in vertebrates. These proteins were ﬁrst
identiﬁed by Moore in 1965 and characterized as “S100” in
consequence for their unique solubility in 100% saturated
solution with ammonium sulphate and were designated by
consecutive arabic numbers placed behind the stem symbol,
for example, s100a1, s100a2, s100a3,a n ds of o r t h[ 4]d u e
to their clustered organization on human chromosome
1q21.
Each S100monomercontainstwoEF-handCa2+ binding
domains interconnected by an intermediate region (hinge
region) (Figure 1)[ 6] exerting unique features when com-
pared with other EF-hand proteins. First, the two EF hands
in each monomer diﬀer in sequence and aﬃnity for Ca2+
binding. The c-terminal EF hand contains the classical
canonical Ca2+ binding motif and ligates Ca2+ in a similar
manner to calmodulin and troponin C, resulting in Kd
10–50μM. The NH2-terminal pseudo-EF hand contains
two additional amino acids and is a characteristic of
S100 proteins. Consequently, Ca2+ aﬃnities decreased to
aK d between 200–500μM( r e v i e w e di n[ 6]). Importantly,
Ca2+ aﬃnity is regulated by posttranslational mechanism
facilitating Ca2+ binding and activation of S100 proteins
even at nanomolar free Ca2+ concentrations. Ca2+ binding
eventually triggers exposure of a hydrophobic epitope which
is believed to mediately represent a major interaction site
enabling accommodation of target proteins through the
exposure of a hydrophobic epitope that surface represents
the interaction site of most S100 proteins for the binding of
target proteins (Figure 2). The second unique characteristic
compared to EF-hand proteins of S100 proteins is their
dimeric nature, as it has been shown both in vivo and
in vitro that S100 proteins form noncovalent homo- and
heterodimers (Figure 2). Third, S100 proteins are expressed
in a tissue- and cell- speciﬁc fashion, pointing to higher
degree of speciﬁcation. The most abundant S100 protein
isoform in cardiac and skeletal muscle is S100A1 among
other S100 isoforms such as S100A4, S100A6, and S100B and
in heart S100A1 is mainly found in ventricular cardiomy-
octes.
3. S100A1—A Member of
the S100 ProteinFamily
In a wide range of small (mouse, rat) and large (rabbit,
dog, swine) animals, S100A1 is preferentially found in the
heart and in lower concentrations in skeletal muscle [8–
10]. Healthy human tissue exhibits a similar distribution
[11], and most recently, large-scale analyses of the human
transcriptome by Su et al. [12] and Shmueli et al. [13]
comprehensively conﬁrmed that the human heart is the
predominant location of S100A1. S100A1 expression steadily
increases during cardiac development in mice and reaches
a plateau in ventricular myocardium in the postnatal state
[14]. Estimations of total intracellular concentrations of
S100A1 in isolated murine and rat left ventricular myocytes
revealed a range between 40 to 200nM ([12], V¨ olkers M,
unpublished observations).
In the adult heart, S100A1 protein is not uniformly
expressed but exhibits its highest mRNA and protein levels
in the left ventricle, with lower concentrations in the
right ventricle and atria [6, 15]. Analysis of the S100A1
promoter in rodents identiﬁed a subset of transcription-
factor consensus sequences (i.e., homeobox protein NK-2
homolog E, myocyte enhancer factor-2, GATA4) [14] that
are well known to drive cardiac-speciﬁc gene expression
of cardiac troponin C or calsequestrin and potentially to
convey predominant cardiac expression of S100A1. First
clinical interest in S100A1 has been sparked due to its altered
expression in diseased myocardium.
3.1.ProteinStructure. TheS100A1monomerwithamolecu-
lar weight of 10.4kDa consists of two EF-hand Ca2+ binding
motif connected by a hinge region. In each EF-hand, a
Ca2+ binding loop is ﬂanked by α-helices, resulting in a
helix-EF-hand-helix arrangement. Helix 1 and II ﬂank the
n-terminal loop, whereas helices III and IV ﬂank the c-
terminal loop (Figure 1). Stabilization of the homodimer
occurs independent of Ca2+ binding through hydrophobic
bonds between helices I and I’ of each monomer [6]. After
Ca2+ binding each monomer undergoes a conformational
change resulting in the exposure of a hydrophobic pocket in
the C-terminus which is believed to be the major docking
site for Ca2+-dependent interactions between S100A1 and
its target proteins. This pocket consists of residues of the
hinge region, helix III and the C-terminus. Since residues
within the hinge region and C-terminus display the greatest
sequence variability among S100 isoforms, they are viewed
to mediate isoform-speciﬁc target recognition [6]. Ca2+
binding to individual EF-hands in the S100A1 dimer has
been estimated to occur with a Kd of 200–500μMa t
the N-terminal and a Kd of 10–50μM at the C-terminal.
However, Ca2+ aﬃnity of both sides is tightly regulated byJournal of Biomedicine and Biotechnology 3
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Figure 1: Schematic depiction of the secondary structure of an S100 protein. The monomeric structure consists of a repetitive
EF-hand motif, whereas eachCa
2+-binding Loop (Loop I and II) is ﬂanked by α-helices. The N-terminal and the C-terminal EF
hands are connected by a linker region (hinge region). The hinge region and the C-terminal extension (boxed in red) display the
least amount of sequence homology among S100 paralogs. Reproduced with modiﬁcations from Donato [5]. [http://www.ncbi.nlm
.nih.gov/pubmed/11390274?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed ResultsPanel.Pubmed RVDocSum&ordinalpos=9].
posttranslational mechanism, that is, redox dependent S-
glutathionylation of cysteine residues which enables S100A1
to sense Ca2+ even at nanomolar concentration (see below).
3.2. Cardiac Subcellular S100A1 Location. Dependent on
the Ca2+ binding in adult cardiomyocytes, S100A1 mainly
resides on the SR, mitochondria and myoﬁlaments. At the
molecular level, S100A1 has been shown to interact with the
cardiac ryanodine receptor (RyR2) [16–19], the SR Ca2+-
ATPase 2a (SERCA2a)-phospholamban (PLB) complex [16,
20, 21], the F1 portion of the mitochondrial ATP synthase
[22] mostly in a Ca2+-dependent manner and acts also as
a binding partner for the giant myoﬁlament protein titin
[23, 24]. As mentioned, Ca2+ binding triggers exposure
of hydrophobic epitope mainly dened by residues within
the S100A1 hinge region and COOH-terminal extension
(Figure 2)[ 7]. Because most actions of S100A1 apparently
rely on transition to its Ca2+-activated state, it is important
to note that recent studies provided ﬁrst evidence for
redox-dependent posttranslational control of S100A1’s Ca2+
sensitivity. NO-dependent S-glutathionylation of a single
cysteine residue within the hydrophobic COOH terminus
eventually facilitated binding of Ca2+ at nanomolar con-
centrations reﬂecting diastolic Ca2+ levels in cardiomyocytes
[25, 26]. The only S-nitrosylation site of S100A1 is its
unique Cys-85 residue. Recent studies indicate that under
physiological conditions the ability of S100A1 protein to act
as a calcium receptor can be turned on by glutathionylation
(cysteinylation) of its Cys85 residue and oﬀ by reduction of
the mixed disulﬁde S100A1–glutathione (S100A1–cysteine)
species. To our knowledge no studies in cardiomyocytes exist
which investigate the basal redox state of S100A1. However
preliminary data indicate that the addition of reducing
agents to the cardiomyocytes abolished the inotropic eﬀects
of S100A1 in vitro (M. Volkers, unpublished data).
Redox and NO-related posttranslational modiﬁcation of
single cysteine residue might therefore enable S100A1 to
sense spatially deﬁned short-term as well as long-term global
Ca2+ oscillations in cardiac cells over a broad concentration
range enabling its interaction with target proteins such as
RyR and SERCA. However, the impact of altered redox
conditions and NO homeostasis on S100A1 actions in
myocardium has not yet been tested.
4.MolecularTargets andPhysiological
FunctionsinCardiacMyocytes
4.1. Lesson from Genetically Altered Miced. Gain- and loss-
in-function studies comprehensively characterized S100A1
as a unique molecular inotrope in vivo and ex vivo.
Increasing S100A1 protein levels in isolated adult and
neonatal cardiomyocytes enhanced both their systolic and
diastolic performance through modulation of cellular Ca2+
handling and myoﬁlament function [17, 19, 20, 24, 27].
Cardiac-speciﬁc overexpression of S100A1 in mice displayed
a phenotype of chronically heightened cardiac performance
without detrimental eﬀects on survival or development of
cardiac hypertrophy [19]. The S100A1-mediated increase
in cardiac performance is independent of beta-adrenergic
stimulation and is even preserved under stimulation with
catecholamines. Expression analysis yielded that S100A1-
mediated inotropic eﬀects are neither the result of altered
abundance of SR and sarcolemmmal Ca2+ regulators, respec-
tively, nor that they depend on β-AR signalling [2, 15, 17–19,
21, 28–35]. To our knowledge, the apparent independence
of S100A1 inotropic actions from the β-AR signalling
pathway is a unique feature of the Ca2+ sensing protein and
of particular importance in cardiovascular physiology and
therapy.
In line with cardiac speciﬁc overexpression of S100A1
in transgenic mice, viral-based overexpression of S100A1 in
rabbit and rat hearts and isolated cardiomyocytes recapit-
ulated the hypercontractile phenotype based on enhanced
Ca2+ cycling but independent, and additive to beta-AR
signalling [15, 17, 18, 33, 34]. Therefore, it is interesting
to note that acute or chronic elevated S100A1 proteins
in cardiomyocytes induce sustained cardiac inotropy, with-
out toxic eﬀects to the cardiomyocytes. This is clinically
importantbecausechronicinotropicstimulationoftheheart
through activation of the beta-receptors or downstream
eﬀectors such as PKA eventually led to cardiac hypertrophy
and failure.4 Journal of Biomedicine and Biotechnology
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Figure 2: The three-dimensional structure of S100A1 as deter-
mined by NMR spectroscopy. (a) S100A1 in the apo state: S100A1
is composed of two identical subunits connected by a linker region
(hinge region). Dimerization occurs in an antiparallel manner. (b)
S100A1 in the Ca2+ bound state: Ca2+ binding to both the N- and
C-terminal motif results in an altered orientation of H3/4 and the
hinge region uncovering hydrophobic residues for the interaction
with target molecules. S100A1 residues 75–94 are indicated by the
red box. Reproduced with modiﬁcations from Wright et al. [7].
In contrast, heterozygous and homozygous S100A1
knockout (SKO) mice showed unaltered in vivo baseline
cardiac function and heart rate, but displayed deﬁciencies
in their contractile function in response to β-AR stimulation
and enhanced transsarcolemmal Ca2+ inﬂux [36].
This is interesting to note because heterozygous SKO
hearts, with only 50% of S100A1 protein levels found
in wild-type hearts, exhibit the same acute defects than
homozygous SKO hearts with complete lack of S100A1
expression. Thus >50% of normal left-ventricular S100A1
protein levels are apparently required for cardiac adaptation
to acute hemodynamic stress. Of note, loss of β-AR-
dependent inotropy in SKO mice occurs despite regular β-
AR signaling ranging from unaltered β-AR density to proper
PKA-dependent target phosphorylation, thereby indicating
that β-AR-mediated positive inotropy essentially relies on
normal S100A1 protein levels in the heart.
Additional exploration of isolated S100A1 knock-out
cardiomyocytes revealed blunted Ca2+ transients in response
to sympathetic stimulation and increased extracellular
[Ca2+][ 31]. This is mainly mediated by a decreased Ca2+
release (and reduced SR Ca2+ load). Similar results were
obtained in neonatal ventricular cardiomyocytes, with a
S100A1 protein knockdown to 20–30% of control protein
levels [22].
Thus defective mobilization of Ca2+ from intracel-
lular stores might provide a reasonable mechanism for
the impaired inotropic reserve in S100A1-deﬁcient and -
depleted cardiomyocytes. In line with this, murine S100A1
knock out ventricular cardiomyocytes have enhanced l-type
Ca2+ current [ICa,L] (Most P, unpublished data), which
indicates that desensitized Ca2+ induced Ca2+ release (CICR)
under basal conditions might be compensated by increased
[ICa,L].
4.2. Molecular Targets: Sarcoplasmic Reticulum in Car-
diac Myocytes. Studies focused on mechanisms underlying
S100A1 inotropic actions provided evidence that S100A1
targets SR but not transsarcolemmal Ca2+ ﬂuxes in ventric-
ular cardiomyocytes. Several studies identiﬁed the impact of
S100A1 on intracellular Ca2+ homeostasis and consistently
found that S100A1 increases systolic and diastolic perfor-
mance through an enhanced Ca2+ induced Ca2+ release
and augmented SR Ca2+ reuptake [17–19, 21, 27, 31]. At
the subcellular level, endogenous S100A1 displays a striated
like pattern in ventricular cardiac myocytes and is found
at the junctional and longitudinal sarcoplasmic reticulum.
Accordingly, S100A1 was found to colocalize and interact
with SERCA2 and RyR2 in a Ca2+-dependent manner in
human, mouse and rat myocardium.
In line with Ca2+-dependent conformational changes,
binding studies identiﬁed the S100A1 COOH terminus
(S100A1ct) as the critical structure for the interaction with
theSERCA-PLBcomplex[18].Functionalanalysisinisolated
SR vesicles and intact cardiomyocytes showed that S100A1
apparently stimulated SERCA2 activity resulting in increased
SR Ca2+ reuptake and enhanced SR Ca2+ load. In isolated SR
vesicles a similar increase in SERCA activity was obtained
with S100A1ct consisting of the c-terminal amino acid
residues 75–94, which indicates the crucial role of helix IV
for the Ca2+ dependent functions of S100A1[18].
The underlying molecular mechanism has not been
explored yet, but it is important to note that neither S100A1
nor S100A1ct aﬀects PLB phosphorylation at serine 16 or
threonine 17 sites, suggesting that neither PKA nor CaMKII
are involved in S100A1-mediated SERCA2 regulation. This
might also indicate that S100A1 does not limit accessof these
kinases to their speciﬁc phosphorylation sites [17].
S100A1 binding to the RyR also seems to be Ca2+-
dependent since mapping studies also identiﬁed S100A1ct
as the critical S100A1 epitope for its RyR2 interaction [27].
RecentstudiesfoundthatS100A1canbindtothecalmodulin
(CaM)bindingdomaininthecytoplasmicportionofskeletal
ryanodine receptor isoform (RyR1), which is highly con-
served between RyR1 and RyR2 [37, 38]. S100A1 modulates
both diastolic and systolic RyR2 functions and thereby alters
frequency and characteristics of elementary SR Ca2+ eventsJournal of Biomedicine and Biotechnology 5
(Ca2+ sparks)andCa2+ inducedSRCa2+ release,respectively.
At nanomolar free Ca2+ concentrations, S100A1 decreased
3H-ryanodine binding to the SR Ca2+ release channel, sug-
gesting an inhibitory eﬀect on RyR2 opening under diastolic
conditions [18, 20]. In line with this, S100A1 interaction
with RyR2 even at diastolic Ca2+ concentration [150nM]
decreased Ca2+ spark frequency and diastolic SR Ca2+ leak
in quiescent rabbit cardiac myocytes and cardiac SR vesicle
preparations, which indicates that S100A1 can improve
RyR2 closure during cardiomyocyte relaxation [27]. In
contrast, at micromolar systolic Ca2+ concentrations S100A1
provoked increased 3H-ryanodine binding in isolated SR
vesicles [18]. Accordingly, a recent study conﬁrmed that
S100A1 increased fractional Ca2+release of the SR in voltage-
clamped rabbit cardiomyocytes, suggesting that S100A1 can
improve excitation-contraction coupling gain in cardiac
myocytes under systolic conditions [20]. Taken together,
these data support the hypothesis that S100A1 promotes
RyR2 closure during diastole but can augment systolic RyR2.
The diﬀerential eﬀects predict more than only one binding
site at the RyR2 and this notion is further supported by
recent mapping studies. At least three diﬀerent S100A1
binding domains have been identiﬁed with diﬀerent binding
aﬃnities within the cytoplasmic portion of the RyR [39].
FurtherfunctionalanalysesconﬁrmedthatofS100A1actions
on diastolic RyR2 function neither changed FKBP12.6 not
sorcin stoichiometry with the RyR2 channel [27]. Therefore
it is attractive to hypothesize that both inhibitory and
stimulatory bindings sites for S100A1 might coexist at the
RyR2, which eventually account for physiological normal
diastolic and systolic performance of the SR Ca2+ release
channel. Moreover, given the redox sensitivity of the RyR,
NO-dependent posttranslational modiﬁcations of S100A1
might contribute to the actions on the SR release channel,
that is, through transfers of NO moieties. In summary, the
precise mechanism underlying S100A1-mediated regulation
of RyR2 remains to be determined, but evidence points
toward a biphasic modulation of RyR2 activity.
Interestingly, it has been shown that S100A1 neither
altered L-type Ca2+ current nor sodium-calcium exchanger
(NCX) reverse or forward mode in adult ventricular car-
diomyocytes [27] and similar results were found for intra-
cellular S100A1 in neonatal ventricular cardiac myocytes
[21]. These results further support the notion that enhanced
cardiomyocyte S100A1 proteins do not evoke cardiac hyper-
trophy, because the S100A1 Ca2+ sensor does not seem to
enhance subsarcolemmal Ca2+ ﬂuxes participating in Ca2+
dependent hypertrophic cardiac growth [19, 31].
4.2.1. Molecular Targets: Sarcomere. Inotropic actions of
S100A1 are apparently not restricted to the SR, because
S100A1 has been shown to regulate both myoﬁlament
Ca2+ sensitivity and diastolic compliance. S100A1 has been
detected at diﬀerent sites within the cardiac sarcomere,
suggesting a possible role in myoﬁlament function [23, 24,
40–42]. S100A1 has been detected at the Z-line, at the
periphery of the M-lines as well as within I- and A-bands.
In the I-band, Ca2+-dependent interaction with the PEVK
subdomain of titin has been shown to result in improved
sarcomeric compliance [23, 24]. It remains to be established
if the binding partner in the A-band is also titin or another
thick-ﬁlamentprotein.Granzierandcolleagueshypothesized
if S100A1 does bind titin in the A-band, the location of the
binding sites suggests interaction with titin’s super-repeat
domains.
Based on their results, Granzier and colleagues hypothe-
sized that S100A1 inhibition of titin-actin interaction might
result in reduced precontractile titin-based passive tension.
In addition, it has been shown that S100A1 can reduce
myoﬁlament Ca2+ sensitivity without aﬀecting maximal
force development and PKA- and PKC-dependent troponin
I phosphorylation. As a result, S100A1 might facilitate dias-
tolic Ca2+ dissociation from myoﬁlaments thereby improv-
ing cardiac relaxation by an additional, SR-independent
mechanism. At present, it is unknown whether S100A1 has
additional sarcomeric targets warranting further studies to
determine the functional role of S100A1 location at Z-disc
adjacent protein structures.
4.2.2. Molecular Targets: Additional Targets-Mitochondria.
B¨ oerries et al. provided ﬁrst evidence that S100A1 is
found in cardiac mitochondria by immunoﬂuorescence and
immunoelectron microscopy. In the mitochondria S100A1
interactswiththeF1-ATPaseinaCadependentmanner[22].
ThisresultedinenhancedactivityoftheATPgeneration.The
same study identiﬁed the adenine nucleotide translocator
(ANT) as a mitochondrial S100A1 target. This suggests that
interaction of S100A1 with ANT might inﬂuence the ADP
and ATP exchange between the mitochondria and the cyto-
plasm. This might also be involved in the regulation of car-
diac apoptosis, as another study yielded antiapoptotic eﬀects
of S100A1 in isolated neonatal rat ventricular myocytes
[28]. In line with this, decreased S100A1 protein levels
resulted in a reciprocal energetic phenotype with decreased
ATP-levels and enhanced cardiomyocyte apoptosis. These
ﬁndings support a crucial role for S100A1 in cardiac energy
homeostasis [22]. Additional studies are underway to clarify
the impact of S100A1 on the interplay between the SR and
mitochondria.
4.3. Cardiomyocyte Ca2+ Handling and Contractile Perfor-
mance. S100A1 plays an important role in cardiac myocytes
Ca2+ cycling and contractile performance. Based on the
molecular targets, numerous studies have shown that the
overall eﬀect of increased S100A1 protein levels can increase
intracellular Ca2+ cycling, SR Ca2+ load, and contractile
performanceinﬁeld-stimulatedmice,rat,andrabbitventric-
ular myocytes. These changes in cardiomyocyte performance
most likely reﬂect altered function of S100A1 molecular
targets as discussed above. Given the fact that S100A1
enhances both SERCA2 activity and diastolic RyR2 diastole,
combined actions most likely contribute to enhanced SR
Ca2+ load and accelerated cardiomyocyte relaxation. In addi-
tion, improved myoﬁlament Ca2+ dissociation in concert
with reduced presystolic passive tension might contribute to
improved diastolic function. In systole, increased SR Ca2+6 Journal of Biomedicine and Biotechnology
load, in concert with enhanced systolic RyR2 opening even-
tually represents a powerful mechanism by which S100A1
can augment systolic Ca2+ transients and cardiac contractile
performance (Figure 3).
Insummary,severalimportantconclusionsandhypothe-
ses can be drawn from these results: ﬁrst S100A1 is a molecu-
lar inotrope in cardiomyocytes exerting a PKA-independent
enhancement of cardiac Ca2+ cycling thereby acting beyond
and independently of cAMP-dependent signaling. Secondly,
S100A1 speciﬁcally targets SR Ca2+ ﬂuxes, improving both
systolic SR Ca2+ release capability (enhances systolic RyR2
activity) and diastolic SR Ca2+ storage capability (decreases
diastolic RyR2 open probability and enhances SERCA2a
activity. The synchronous enhancement of SERCA2a activity
and decreased RyR2 activity in diastole is a hitherto unique
and potentially synergistic molecular mechanism which
ampliﬁes its inotropic actions but might help to prevent
Ca2+-triggered arrhythmias; ﬁnally, S100A1 modulation of
cardiac titin function might adapt cardiac passive tension
and sarcomeric Ca2+ sensitivity to improved Ca2+ cycling,
thereby facilitating diastolic cardiac performance. Finally,
S100A1 mitochondrial actions might reﬂect a mechanism
to couple Ca2+-dependent energetic demand with mito-
chondrial energy production. Figure 3 provides a scheme to
illustrate the molecular mechanism of S100A1 in a normal
cardiomyocyte.
4.4.SkeletalMuscleCa2+ Handling. Skeletalmuscleexpresses
S100A1 at lower levels than cardiac muscle [30]. However,
numerous studies have demonstrated an important role of
S100A1 in skeletal muscle EC-coupling [30, 37, 38, 43–45].
S100A1 binds to RyR1 and potentiates its open probabil-
ity, which might be regulated by three identiﬁed S100A1
binding sites at the RyR1 [39]. Interestingly, one of the
binding site overlaps with a Ca2+-dependent CaM binding
domain. In saponin skinned muscle ﬁbers, addition of
recombinant S100A1 protein enhanced SR Ca2+ release and
isometric force development in a dose-dependent manner
both in fast- and slow-twitch skeletal muscle ﬁbers [30]a n d
maximal eﬀects were seen at nanomolar S100A1 protein
concentrations. However, S100A1 neither activated RyR1 in
its closed state nor initiated SR Ca2+ release at diastolic
Ca2+ concentrations in the presence of physiologic Mg2+
concentrations. In contrast to cardiac myocytes, S100A1
neither enhanced SR Ca2+ load nor altered Ca2+ sensitivity of
skeletal muscle myoﬁlaments indicating that S100A1 action
in skeletal muscle might be limited to SR Ca2+ release sites
and eventually mitochondria [30].
In S100A1 deﬁcient skeletal muscle ﬁbers Wright et al.
most recently found that voltage-induced SR Ca2+ release
is decreased resulting in diminished global Ca2+ transients
and contractile force development [37]. The same study
revealed that viral-based S100A1 gene delivery can rescue the
phenotype providing ultimate evidence for the hypothesis
that S100A1 plays a signiﬁcant physiological role in skeletal
muscle EC-coupling. At a molecular level, the authors
further showed that S100A1 and CaM can compete for the
same binding site at the RyR1 in a Ca2+-dependent manner
and identiﬁed RyR1 residues 3416–3427 as the putative
common binding domain [38].
Interestingly, this interaction involves the hydrophobic
pocketofS100A1,whichisexposedinitsCa2+ activatedstate.
At this point it is interesting to note that the S100A1/RyR1
binding domain is involved in the intersubunit interactions
of the RyR1 as well as close in space to distal parts of
the channel, so that the authors developed a model where
S100A1 proteins might be involved in linking one or two
subunits of the RyR tetramer. Recently another interesting
study by the same group showed that decreased SR Ca2+
releaseinS100A1KOﬁbresisresponsibleforthesuppression
of the temporally delayed component of intramembrane
charge movement, Qgamma, which might operate as an
indicator of optimized local Ca2+ release at the triad junction
in skeletal muscle [44, 45]. In regard of the previously
discussed importance of S100A1 in cardiac muscle, it is
tempting to speculate that S100A1 plays a key role in skeletal
muscle physiology.
Taken together, these data indicate that S100A1 plays
a signiﬁcant role in skeletal muscle EC coupling through
modulation of RyR1 function, but not through modulation
of SR Ca2+ load. Further studies are necessary to determine
the impact of S100A1 in skeletal muscle disease to determine
thepathophysiologicalroleatherapeuticpotentialofS100A1
in skeletal muscle disorders like congential myopathies.
5.S100A1inDiseasedMyocardium
The discovery of altered S100A1 protein abundance in
failing human myocardium ﬁnally raised the question
for a therapeutic potential of S100A1 since progressively
diminished S100A1 mRNA and protein levels characterize
failing human myocardium [46] .Ar e c e n tp r o o fo fc o n c e p t
study employing both cardiac S100A1 transgenic and knock-
out mouse models has provided evidence that diminished
S100A1 protein levels critically contribute to progressive
contractile dysfunction in postischemic heart failure (HF)
and death [31]. The same study indicated that preserved
cardiomyocyte S100A1 protein levels could actually prevent
development of postischemic HF and cardiac death. In line
with S100A1 molecular actions in isolated cardiomyocytes,
remote myocardium from infarcted S100A1-overexpressing
hearts showed preserved SR Ca2+ handling while S100A1
deﬁciency resulted in abnormal SR Ca2+ content and ﬂuxes.
In addition, S100A1 knock-out mice subjected to transaortic
constriction showed accelerated deterioration of cardiac
performance and transition to heart failure [36]. Therefore,
normal S100A1 cardiac expression levels appear to be
essential to cope with increased workload due to ischemic
loss of myocardium or chronically elevated afterload.
Abnormal cardiomyocyte S100A1 protein levels have
further been recapitulated in vitro by chronic stimulation
with diﬀerent hypertrophic stimuli like phenylephrine and
endothelin-1[31].InlightofthelowabundanceofS100A1in
neonatal and developing hearts, downregulation of S100A1
in the course of cardiac hypertrophy could therefore be
considered as a part of fetal gene reprogramming.Journal of Biomedicine and Biotechnology 7
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Figure 3:ProposedmodelforS100A1inotropicactionsincardiomyocytes.(a)Duringexcitation-contractioncoupling,theactionpotential-
dependent opening of the L-type Ca2+ channel (LTCC) results in a transsarcolemmal Ca2+ entry which triggers sarcoplasmic reticulum (SR)
Ca2+ release via Ryanodine Receptor 2 (RyR2) that in turn activates myoﬁlament cross-bridge cycling and mechanical contraction. During
diastole, the SR Ca2+ reuptake is conducted by the SR Ca2+ ATPase (SERCA), whereas the sodium-calcium exchanger (NCX) extrudes Ca2+
from the cardiomyocyte to keep steady-state conditions. (b) S100A1 interacts with both RyR2 and the SERCA-Phospholamban (PLB)-
complex and is present at myoﬁlaments and mitochondria. Increased S100A1 protein levels result in an enhanced systolic SR Ca2+ release via
RyR2 without inﬂuencing LTCC activity. Augmented SR Ca2+ release is balanced by an intensiﬁed SERCA activity leading to an improved
Ca2+ cycling and a raised force generation. Additionally, the S100A1/F1-ATPase interference in mitochondria is associated with an enhanced
generation of cytoplasmic ATP in cardiomyocytes. Moreover, S100A1 inhibits the actin-titin interactions in the sarcomere, resulting in a
reduced precontractile passive tension [24].8 Journal of Biomedicine and Biotechnology
ThebindingofS100A1tothesarcomerecouldcontribute
to an altered diastolic function in diseased myocardium.
Reduced binding of S100A1 to titin in this context could
theoretically contribute to an increased precontractile titin-
based passive tension. Interestingly, the myoﬁlament relax-
ationseemstobedependentontheintracellularATP-balance
[47]. Because S100A1 deﬁciency reduced intracellular ATP-
levels in cardiac myocytes (see above), it is tempting to
speculate that lower ATP-levels due to S100A1 deﬁciency
contribute to impaired diastolic function in cardiac disease.
Moreover, it has been shown that S100A1 aﬀects micro-
tubules stability in the presence of Ca2+ [48]. Given the
fact that recent work has shown that microtubules increase
viscosity in cardiac hypertrophy and heart failure [49],
further studies are needed to clarify the impact of altered
S100A1 protein expression on diastolic function in cardiac
diseases.
6. Therapeutic Implications and
ClinicalPerspectives
Owing to the pathophysiological relevance of altered S100A1
expression in cardiac disease and therapeutics eﬀectiveness
in clinically relevant experimental acute and chronic HF
animal models, S100A1 might be considered as a future
prototype of a novel class of Ca2+-dependent inotropes.
Intracoronary S100A1 adenoviral and adeno-associated viral
genedeliveryrestoredabnormalS100A1expressioninfailing
hearts thereby improving cardiac performance and reversing
cardiac hypertrophy in vivo [15, 18, 32, 33]. So far, both
RyR2 and SERCA have been considered as major therapeutic
S100A1 targets in failing myocardium given normalization
of dysfunctional Ca2+ cycling via restored SR Ca2+ content,
improved systolic SR Ca2+ release, as well as decreased
diastolic SR Ca2+ leakage. Because S100A1 augments both
SR Ca2+ load and fractional SR Ca2+ release, it is tempting
to speculate that S100A1 promotes inotropic SR Ca2+
handling but potentially limits Ca2+ triggered arrhythmias
by stabilizing the RyR2 during diastole. This notion is based
on the observation that S100A1 gene delivery to normal
and failing cardiomyocytes can prevent β-AR triggered
proarrhythmic SR Ca2+ leak and diastolic Ca2+ waves.
Accordingly, S100A1 knock-out mice display enhanced
proarrhythmic susceptibility in response to sympathetic
stimulation [50] and prevention of this eﬀect might actually
contribute to improved postMI survival in S100A1 trans-
genic mice [51]. These ﬁndings might further substantiate
the clinical relevance of S100A1-mediated regulation of SR
Ca2+ handling through balanced modulation both of RyR2
and SERCA2. Moreover, S100A1 gene delivery in diseased
myocardium exerts robust antihypertrophic eﬀects in vivo
and prevents progressive left ventrical chamber dilatation,
potentially reﬂecting abrogated wall stress and interrupted
sympathetic overdrive. Finally, S100A1 gene therapy also
restored defective energy and sodium homeostasis which are
closely linked to Ca2+ handling abnormalities [18]c l e a r l y
warranting father investigation of the underlying molecular
mechanisms.
From a clinical point of view, it is important to point
out that viral-based S100A1 gene therapy has proven its
therapeutic eﬀectiveness both in an experimental postis-
chemic large-animal HF model [52] and human failing ven-
tricular cardiomyocytes (Most P, unpublished observation).
Retroinfusion-facilitated delivery of AAV9-S100A1 gene via
the anterior coronary vein 2 weeks postMI restored left ven-
tricular performance and prevented transition to contractile
failure as seen in control groups. In line with sustained
improvement of cardiac performance, S100A1 gene therapy
reversed cardiac remodeling and sympathetic overdrive [52].
Moreover, another proof of concept study provided evidence
that S100A1 gene therapy normalized abnormal contractility
and SR Ca2+ handling in failing human cardiomyocytes
and restored a positive force-frequency response in these
cells (Most P, unpublished observations). These translational
studies might actually pave the way for novel S100A1-based
clinical therapies including S100A1 gene therapy of human
HF. However before S100A1 HF gene therapy can become
a clinical reality, careful evaluation of its safety proﬁle
as well as eﬀects on cardiac energetics, arrhythmias and
compatibility with established pharmacological therapies
needs to be conducted in large-animal models. Importantly,
a recent study actually provided ﬁrst evidence that S100A1
gene therapy neither interferes with sympathetic stimulation
nor β-blocker treatment [32].
7. Summary
To improve human health, scientiﬁc discoveries must be
translated into practical applications. Such discoveries typ-
ically begin with clinical observations further requiring basic
research at “the bench” to uncover molecular mechanisms
andproofofpathophysiologicalrelevancebeforeprogressing
to the clinical level, or the patient’s “bedside.” The clinical
discovery of altered S100A1 protein abundance in failing
human myocardium [46] ignited a challenging search for
its pathophysiological relevance and potential therapeutic
impact. Now, almost a decade later, ample evidence indi-
cates that S100A1 functions as a Ca2+-dependent molec-
ular inotrope in cardiomyocytes with unique therapeutic
properties. S100A1 targets several key regulators of SR,
myoﬁlament,andmitochondrialfunctiontherebyenhancing
cardiomyocyte performance. In addition, several lines of
evidence indicates that S100A1 plays a signiﬁcant role in
skeletal muscle function but its pathophysiological relevance
and therapeutic potential in skeletal muscle disorders have
not been fully explored yet. Dysregulation of cardiomyocyte
S100A1 protein expression, however, accelerates develop-
ment of cardiac hypertrophy, progression towards HF and
cardiac death. Translational studies provided evidence for
long-term rescue of cardiac performance and reversed
remodeling in several small and large HF animal models.
Importantly, S100A1 therapeutic actions extend to human
failing myocardium showing restored contractile perfor-
mance based on improved SR Ca2+ handling in S100A1-
treated human failing cardiomyocytes [17]. Due to these
ﬁndings, S100A1-based HF therapies further progress toJournal of Biomedicine and Biotechnology 9
the clinical level moving forward towards ﬁrst clinical safety
trials. One could therefore speculate that S100A1 gene
therapy might be applicable both to acute and chronic
cardiacdysfunctionpotentiallybeneﬁtingpatientswithacute
cardiac decompensation as chronic HF. In theory, S100A1
gene therapy for HF may oﬀer a promising and novel mode
ofactionthatwillnotonlypromotebeneﬁcialcardiomyocyte
EC Ca2+ handling but also potentially limit arrhythmias
through stabilization of RyR and decrease in diastolic Ca2+
leak. Moreover, the impact of S100A1 on the sarcomere and
the mitochondria function completes the unique therapeutic
potential of S100A1.
However, development of S100A1-based therapeutic will
presumably not replace currently established drug regimens
but rather complement and add on to these therapeutic
strategies. Nevertheless, S100A1 might facilitate a clinical
revival of inotropic therapeutic interventions by targeting
defective Ca2+ cycling and providing future cardiologists
with a novel weapon to combat heart failure.
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